UBS Asset Management Americas Inc. boosted its holdings in shares of Viewray Inc (NASDAQ:VRAY) by 4.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 135,659 shares of the company’s stock after purchasing an additional 6,087 shares during the quarter. UBS Asset Management Americas Inc. owned about 0.14% of Viewray worth $1,195,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Bank of Montreal Can raised its stake in Viewray by 4,390.1% during the 2nd quarter. Bank of Montreal Can now owns 5,882 shares of the company’s stock valued at $52,000 after purchasing an additional 5,751 shares during the period. Parametric Portfolio Associates LLC bought a new stake in Viewray in the 2nd quarter worth approximately $123,000. Stephens Inc. AR increased its stake in Viewray by 9.6% in the 2nd quarter. Stephens Inc. AR now owns 17,420 shares of the company’s stock worth $153,000 after acquiring an additional 1,522 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new stake in Viewray in the 2nd quarter worth approximately $156,000. Finally, State Board of Administration of Florida Retirement System increased its stake in Viewray by 6.8% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 22,940 shares of the company’s stock worth $202,000 after acquiring an additional 1,460 shares during the last quarter.
A number of analysts have issued reports on the company. Cantor Fitzgerald set a $6.00 price objective on Viewray and gave the stock a “buy” rating in a research note on Friday, September 13th. Northland Securities restated a “buy” rating and set a $5.00 price objective on shares of Viewray in a report on Monday, August 19th. ValuEngine upgraded Viewray from a “hold” rating to a “buy” rating in a report on Thursday. Piper Jaffray Companies began coverage on Viewray in a report on Tuesday, June 18th. They set an “overweight” rating and a $15.00 price objective for the company. Finally, Mizuho set a $9.00 price objective on Viewray and gave the company a “buy” rating in a report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $9.55.
Viewray (NASDAQ:VRAY) last issued its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.09). The firm had revenue of $30.17 million for the quarter, compared to the consensus estimate of $25.92 million. Viewray had a negative net margin of 128.13% and a negative return on equity of 67.02%. The company’s revenue for the quarter was up 83.5% on a year-over-year basis. During the same period last year, the firm earned ($0.30) earnings per share. As a group, research analysts anticipate that Viewray Inc will post -1.18 earnings per share for the current fiscal year.
In other news, insider James F. Dempsey sold 21,615 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $8.97, for a total value of $193,886.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James F. Dempsey sold 279,414 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $3.57, for a total value of $997,507.98. Following the completion of the transaction, the insider now directly owns 272,433 shares of the company’s stock, valued at $972,585.81. The disclosure for this sale can be found here. Insiders own 15.48% of the company’s stock.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Featured Article: Municipal Bonds
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.